Market Overview –
The Chronic Kidney Disease (CKD) Market is experiencing significant growth globally due to the rising prevalence of CKD and related risk factors such as diabetes and hypertension. CKD, characterized by a gradual loss of kidney function over time, poses a substantial health burden worldwide. Factors such as aging populations, unhealthy lifestyles, and genetic predisposition contribute to the increasing incidence of CKD.
The Chronic Kidney Disease market is undergoing notable developments, particularly in patients with renal kidney disease. Hemianopsia, characterized by partial blindness in one half of the visual field, can occur as a complication of renal kidney disease. Research into effective management and treatment options is driving advancements in this niche market to improve quality of life for affected individuals.
The market encompasses various treatment options, including medications, dialysis, and kidney transplantation, aimed at managing symptoms and slowing disease progression. Additionally, advancements in diagnostic techniques and therapies drive market growth by improving early detection and management strategies.
In 2022, the market for chronic kidney disease was estimated to be worth USD 65.88 billion. The market for chronic kidney disease is expected to increase at a compound annual growth rate (CAGR) of 5.5% between 2023 and 2030, from USD 69.44 billion in 2023 to USD 101.2 billion.
Growth Boosters and Deterrents
Rising burden of chronic diseases across the world including kidney as well as high blood pressure has rendered the chronic kidney disease market quite profitable. The Kidney Health Australia reveals that healthcare costs pertaining to the existing as well as new cases of kidney disease will touch USD 12 billion by 2022. Going forward, the Centers for Disease Control & Prevention says that close to 15% of Americans are expected to develop chronic kidney disease by 2021. Reports also confirm that a whopping 96% of patients suffering from kidney damage are not even aware of about the condition, which should foster the growth potential of the chronic kidney disease drugs industry in the years ahead. Alarming rise in cases of high blood pressure and diabetes is also bound to create favorable avenues for the global market.
The chronic kidney disease industry also stands to profit from the burgeoning aging population, which is susceptible to various diseases including kidney and urinary disorders. Besides, the heightened preference among patients for minimally invasive procedures along with the surge in technical advances will further enhance the market share over the upcoming period. Canada along with the US house a huge patient pool suffering from chronic kidney and urinary disorders given the prevalence of sedentary lifestyles in these countries. In addition, government funds for developing the healthcare infrastructure should favor the market in subsequent years.
Market Segmentation
The chronic kidney disease industry has been segregated with respect to diagnosis, treatment, indication, and end-user.
The diagnosis-based segments are urine test, blood test, kidney biopsy and imaging test.
Treatment-wise, the market caters to dialysis, kidney transplant and drugs.
The indications covered in the report are polycystic kidney disease, high blood pressure, Type 1 or Type 2 diabetes, and others.
Major market end-user considered in the study are diagnostic centers, hospitals and clinics, and others.
Regional Analysis
The chronic kidney disease industry has been geographically divided into Europe, APAC/Asia Pacific, MEA/Middle East & Africa and the Americas.
The American chronic kidney disease market is in the lead, considering the expanding population of patients affected by kidney diseases and the extensive demand for kidney disease diagnostic tests. Soaring need for new and more effective treatment options for the condition has fostered the growth of the chronic kidney disease market. CDC reports that in the year 2015, close to 120,000 Americans started with the treatment for chronic kidney disease, indicating the rising awareness among the mass about this condition. This prompts more and more patients to come forward and seek treatment for the condition. This factor should ensure sustained market growth throughout the review period for North America.
The European market has been rendered strong by the burgeoning medical device sector and the mounting awareness among people about the risk factors associated with kidney diseases. Additionally, the mounting number of diabetic patients and the large-scale spending on the medical device and drugs industry will further elevate the market position in Europe. Germany is by far the most lucrative market for chronic kidney diseases in the region, in view of the rising emphasis on developing new drugs and the strong government backing to research & development activities.
Asia Pacific is slated to chart the fastest growth trajectory over the ensuing years, largely due to the expanding elderly population, prevalence of stressful lifestyle and the growing patient base. The noteworthy improvement in the quality of treatment lines and diagnosis, along with the surge in purchasing capacity of people across China, Japan and India also push the market demand. The rise in healthcare spending coupled with escalating number of government initiatives aimed at spreading awareness about chronic kidney disease and rising focus on establishing state of the art medical facilities will also foster market expansion rate in the years ahead.
Key Players –
Chronic Kidney Disease companies include Abbott, Siemens, Beckman Coulter, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc, Nova Biomedical, ARKRAY, AstraZeneca, GlaxoSmithKline Plc, and Bayer AG.
Related Reports –
For more information visit at MarketResearchFuture
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek